Actinic Keratosis Treatment Market Forecast 2022 to 2028 | By LEO Pharma, Novartis, Almirall, Biofrontera

According to Future Market Insights (FMI), the global Actinic Keratosis Treatment Market Size was valued at approximately US$ 5.4 billion in 2022 and is expected to reach US$ 8.0 billion by 2028.

The increasing prevalence of actinic keratosis, the increased need for actinic keratosis treatment products, prospective drugs in the pipeline, and the desire for topical therapies are the primary drivers driving the development of the actinic keratosis treatment market. In addition, the rising incidence of skin cancer, combined with an increased desire for minimally invasive procedures, is propelling the actinic keratosis treatment market forward.

To remain ahead of your competitors, request for a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3233

Who Is Winning?

GlaxoSmithKline Plc, Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc., and others are profiled in the actinic keratosis therapy market study. To extend their product range, leading actinic keratosis therapy companies are focusing on acquisitions. For example, Leo Pharma A/S completed the acquisition of Astellas Pharma’s dermatological business in November 2015. With this acquisition, the company expanded their dermatology product portfolio sector. Companies are likewise focusing their efforts on achieving sector leadership. Actikerall, a topical treatment for fairly perceptible and/or moderately thick hyperkeratotic actinic keratosis, was launched in February 2016 by Cypher Pharmaceuticals Inc., confirming their leadership in the topical pharmaceutical industry.

Combination therapies such as topical fluorouracil cryotherapy, PDT plus imiquimod therapy, chemical peels, and 5-FU are the most widely prescribed treatments for actinic keratosis. Convenient administration, reduced risk of pain, and systemic absorption all contribute to their extensive use. Global market leaders are now concentrating on the development of drugs with higher efficacy and fewer side effects that can be used in combination therapy to treat actinic keratosis. Ameluz (2016) was commercialised by Biofrontera AG and is used in conjunction with PDT to treat actinic keratosis.

The development of minimally invasive drug-device combination therapy, as well as fast track regulatory approval for pipeline drugs, will give an altogether new set of therapeutic options for actinic keratosis in the near future.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-3233

Key Takeaways – Actinic Keratosis Treatment Market Study

• Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
• Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
• For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
• Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
• For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
• The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 to 2018 and projections from 2022 to 2028 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-3233

Actinic Keratosis Treatment Market By Category

By Treatment Type:

• Topical Treatment
  • 5-fluorouracil Cream
  • Diclofenac Gel
  • Imiquimod Cream
  • Ingenol mebutate Gel
• Procedural Modality
  • Chemical Peels
  • Cryotherapy
• Photodynamic Therapy
• Others

By Disease Type:

• Clinical AK
• Subclinical AK

By End User:

• Hospitals
• Private Dermatology Clinics
• Laser Therapy Centers
• Cancer Treatment Centers
• Spas and Rejuvenation Centers
• Homecare

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs